Supreme Court: Police May Freeze Bank Accounts under S.102 CrPC in Prevention of Corruption Cases  ||  SC: Arbitrator’s Mandate Ends on Time Expiry; Substituted Arbitrator Must Continue After Extension  ||  SC: Woman May Move Her Department’s ICC For Harassment by Employee of Another Workplace  ||  SC: Women’s Representation Requirement Applies to All Bar Associations in Gujarat  ||  SC: Contempt Power isn’t Judges’ Personal Shield nor a Tool to Silence Legitimate Criticism  ||  SC: Statutory Corporation Can Deduct under S.36(1)(viii) Only for Income from Long-Term Finance  ||  NCLT Kolkata: Costs for Compromise or Arrangement Scheme not Part of Liquidation Expenses  ||  NCLT Ahmedabad: Complaints Against Auditors or Company Secretaries Not Grounds for Company Probe  ||  SC: NCLT Can Forfeit Entire Deposit if Purchaser Defaults on Payment for Liquidation Assets  ||  Meghalaya HC: Non-Signatory or Non-Existent LLP Cannot Claim Arbitration via Group of Companies    

Why drugs are being taken off pharmacy shelves - (21 Mar 2016)

Civil

Headlines in recent days and weeks have reported hundreds, even thousands of drugs being banned from sale in India. Pharmacists are warning of shortages, a kinder way of saying rising prices, while also informing the Drug Controller General of India of the heightening probability of closure of shops, a.k.a., a strike. But why the sudden onset hostility towards certain medicines?

The banning of drugs may seem to have sprung out of the blue but there is method in the pharmacophobia. Circa June of 2013, the Directorate General of Health Services, under the auspices of the Ministry of Health and Family Welfare, released a report, ‘Policy Guidelines for Approval of Fixed Dose Combinations (FDCs) in India’. Prepared under the aegis of Professor C.K. Kokate, the Report considered the prevalence of ‘Fixed Dose Combination’, drugs comprising two or more active ingredients in a fixed ratio. The rationale behind FDCs is simple: two or more ‘actives’ that complement each other or provide the benefit of two products in one swallowing. But, to ensure FDCs’ benefits outweighing their risks, the Report called for called such preparations being based on “convincing therapeutic rationalization and be carefully justified and clinically relevant.” Categories of FDCs were penned and the onus was on manufacturers to show the rationale behind having two or more active ingredients in one preparation.

The Report birthed the ‘Kokate Committee’: tasked with the implementation of recommendations in the report, the Committee has spent over one year perusing thousands of drugs. As of January 2015, the Committee had found only 42.07 per cent of FDCs submitted for perusal as rational, and over 30 per cent as requiring further data or deliberation.

Tags : MINISTRY OF HEALTH   FIXED DOSE COMBINATIONS   RATIONALE  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved